Sugi Predict

Sugi Predict / Compounds / SCHEMBL1290116

SCHEMBL1290116

SCHEMBL1290116

CC1(C)OB(c2ccc(CNC(=O)O)c(F)c2)OC1(C)C

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ROCK1 Q13464 1/20 0.54
▸ LIPG Q9Y5X9 4/20 0.40
▸ LPL P06858 3/20 0.40
▸ HIF1A Q16665 2/20 0.40
▸ CA1 P00915 2/20 0.40
▸ CA2 P00918 2/20 0.40
▸ CA9 Q16790 2/20 0.40
▸ F2 P00734 2/20 0.39
▸ F11 P03951 2/20 0.39
▸ PRSS1 P07477 2/20 0.39
▸ PRSS2 P07478 2/20 0.39
▸ PRSS3 P35030 2/20 0.39
▸ EPHX2 P34913 1/20 0.39
▸ NR1H4 Q96RI1 1/20 0.39
▸ PRMT5 O14744 1/20 0.39
▸ WDR77 Q9BQA1 1/20 0.39
▸ P2RX7 Q99572 2/20 0.38
▸ P4HB P07237 1/20 0.37
▸ EGFR P00533 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20365272 0.90 ROCK1 (0.54) ROCK1LIPGLPLHIF1ACA1
SCHEMBL28616950 0.87 ROCK1 (0.52) ROCK1LIPGLPLHIF1ACA1
SCHEMBL17418791 0.87 ROCK1 (0.52) ROCK1LIPGLPLHIF1ACA1
SCHEMBL29152163 0.87 ROCK1 (0.54) ROCK1LIPGLPLCA1CA2
SCHEMBL16794462 0.86 NPC1 (0.43) ROCK1LIPGLPLHIF1ACA1
SCHEMBL20359137 0.86 ROCK1 (0.51) ROCK1LIPGLPLHIF1ACA1
SCHEMBL26697140 0.86 ROCK1 (0.53) ROCK1CA1CA2CA9
SCHEMBL23303674 0.85 ROCK1 (0.42) ROCK1LIPGLPLHIF1ACA1
SCHEMBL22660021 0.84 AAK1 (0.42) ROCK1LIPGLPLHIF1ACA1
SCHEMBL25216265 0.84 CA1 (0.42) ROCK1LIPGLPLHIF1ACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024129395-A1 BTK INHIBITORS GWYNANT THERAPEUTICS, INC. (US) 2024-06-20 — — WO disclosed
EP-4333899-A1 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE Biogen MA Inc. (US) 2024-03-13 — — EP disclosed
WO-2023086521-A1 BTK INHIBITORS BIOGEN MA INC. (US) 2023-05-19 — — WO disclosed
US-11401272-B2 Heterocyclic compounds as LSD1 inhibitors INCYTE CORPORATION (US) 2022-08-02 — — US disclosed
EP-4026832-A1 PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 Almac Discovery Limited (GB) 2022-07-13 — — EP disclosed
US-20200392143-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS INCYTE CORPORATION 2020-12-17 — — US disclosed
US-10800779-B2 Heterocyclic compounds as LSD1 inhibitors INCYTE CORPORATION (US) 2020-10-13 — — US disclosed
US-10766903-B2 Piperidine derivatives as inhibitors of ubiquitin specific protease 7 ALMAC DISCOVERY LIMITED (GB) 2020-09-08 — — US disclosed
US-10640503-B2 Imidazopyridines and imidazopyrazines as LSD1 inhibitors INCYTE CORPORATION (US) 2020-05-05 — — US disclosed
EP-3626720-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS Incyte Corporation (US) 2020-03-25 — — EP disclosed
EP-3034078-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS Emergent Product Development Gaithersburg Inc. (US) 2016-06-22 — — EP disclosed
WO-2016007731-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION (US) 2016-01-14 — — WO disclosed
US-20150141435-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 2015-05-21 — — US disclosed
US-8962842-B2 2-pyridone antimicrobial compositions EVOLVA SA (CH) 2015-02-24 — — US disclosed
EP-2670410-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES Evolva SA (CH) 2013-12-11 — — EP disclosed
US-20130252882-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EVOLVA SA (CH) 2013-09-26 — — US disclosed
US-20130245035-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2013-09-19 — — US disclosed
EP-2621491-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS Evolva SA (CH) 2013-08-07 — — EP disclosed
WO-2012104305-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EVOLVA SA (CH) 2012-08-09 — — WO disclosed
WO-2012047487-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2012-04-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11401272-B2 Heterocyclic compounds as LSD1 inhibitors KDM1B, KDM1A, DOT1L ROCK1 1257/4885LIPG 1842/4885LPL 3226/4885
US-20200392143-A1 HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS KDM1B, KDM1A, DOT1L ROCK1 1257/4885LIPG 1842/4885LPL 3226/4885
US-20150141435-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS TOP2A, TOP1, TOP2B ROCK1 1537/4885LIPG 3733/4885LPL 3962/4885
US-20130252882-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES CUL4A, DCAF15, CUL4B ROCK1 4340/4885LIPG 4322/4885LPL 4431/4885
US-10766903-B2 Piperidine derivatives as inhibitors of ubiquitin specific protease 7 USP7, USP5, UBA7 ROCK1 4071/4885LIPG 2600/4885LPL 2569/4885
US-10800779-B2 Heterocyclic compounds as LSD1 inhibitors KDM1B, KDM1A, DOT1L ROCK1 1257/4885LIPG 1842/4885LPL 3226/4885
US-20130245035-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS TOP2A, TOP1, TOP2B ROCK1 2507/4885LIPG 4028/4885LPL 4409/4885
US-10640503-B2 Imidazopyridines and imidazopyrazines as LSD1 inhibitors KDM5A, KDM1A, KDM1B ROCK1 832/4885LIPG 4054/4885LPL 4359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.